Pacific Study Phase 2 now enrolling
The Phase 2 PACIFIC study will enroll approximately 58 patients with moderate-to-severe pruritus due to PBC or PSC. The study comprises a 6-week double-blind treatment period in which subjects are randomized 1:1 to 100mg EP547 or placebo, dosed orally once daily, followed by a 6-week open label extension period in which all subjects receive EP547. The primary efficacy endpoint is the change from baseline to week 6 in itch intensity. Read more.